DRUG
Price
$75.93
Change
-$1.91 (-2.45%)
Updated
Jul 13 closing price
Capitalization
727.08M
Intraday BUY SELL Signals
SANA
Price
$3.64
Change
-$0.21 (-5.45%)
Updated
Jul 13 closing price
Capitalization
1.02B
16 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DRUG vs SANA

DRUG vs SANA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DRUG vs. SANA commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a StrongBuy and SANA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (DRUG: $75.93 vs. SANA: $3.64)
Brand notoriety: DRUG and SANA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DRUG: 48% vs. SANA: 42%
Market capitalization -- DRUG: $727.08M vs. SANA: $1.02B
DRUG [@Biotechnology] is valued at $727.08M. SANA’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DRUG’s FA Score shows that 1 FA rating(s) are green whileSANA’s FA Score has 0 green FA rating(s).

  • DRUG’s FA Score: 1 green, 4 red.
  • SANA’s FA Score: 0 green, 5 red.
According to our system of comparison, DRUG is a better buy in the long-term than SANA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DRUG’s TA Score shows that 5 TA indicator(s) are bullish while SANA’s TA Score has 6 bullish TA indicator(s).

  • DRUG’s TA Score: 5 bullish, 5 bearish.
  • SANA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SANA is a better buy in the short-term than DRUG.

Price Growth

DRUG (@Biotechnology) experienced а +13.92% price change this week, while SANA (@Biotechnology) price change was -8.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.

Reported Earning Dates

SANA is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Biotechnology (-3.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SANA($1.02B) has a higher market cap than DRUG($727M). DRUG YTD gains are higher at: -2.704 vs. SANA (-10.565). DRUG has higher annual earnings (EBITDA): -31.11M vs. SANA (-192.2M). DRUG has more cash in the bank: 310M vs. SANA (101M). DRUG has less debt than SANA: DRUG (82.1K) vs SANA (75.3M). DRUG (0) and SANA (0) have equivalent revenues.
DRUGSANADRUG / SANA
Capitalization727M1.02B72%
EBITDA-31.11M-192.2M16%
Gain YTD-2.704-10.56526%
P/E RatioN/AN/A-
Revenue00-
Total Cash310M101M307%
Total Debt82.1K75.3M0%
TECHNICAL ANALYSIS
Technical Analysis
DRUGSANA
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 12 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
DRUG
Daily Signal:
Gain/Loss:
SANA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GIDAX9.39N/A
N/A
Goldman Sachs Intl Eq Div & Prem A
BPAIX37.16N/A
N/A
Boston Partners All Cap Value Instl
RIDHX27.51N/A
N/A
American Funds Income Fd of Amer R-5E
JSJIX17.71N/A
N/A
JHancock Small Cap Dynamic Growth I
JAOSX63.88-1.17
-1.80%
Janus Henderson Overseas T

DRUG and

Correlation & Price change

A.I.dvisor indicates that over the last year, DRUG has been loosely correlated with BIVI. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DRUG jumps, then BIVI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRUG
1D Price
Change %
DRUG100%
-2.45%
BIVI - DRUG
39%
Loosely correlated
-27.75%
RGNX - DRUG
34%
Loosely correlated
-8.60%
BEAM - DRUG
33%
Loosely correlated
-5.14%
PSTV - DRUG
33%
Poorly correlated
+4.25%
SANA - DRUG
32%
Poorly correlated
-5.45%
More